EU5 Nephrologists Report a Decreasing Trend in the Treatment Prevalence of ESAs in the Haemodialysis Patient Population

  EU5 Nephrologists Report a Decreasing Trend in the Treatment Prevalence of
                 ESAs in the Haemodialysis Patient Population

Biosimiliar ESAs Patient Share Remains Minimal in CKD Non-Dialysis

PR Newswire

EXTON, Pa., Feb. 7, 2013

EXTON, Pa., Feb. 7, 2013 /PRNewswire/-- BioTrends Research Group, one of the
world's leading research and advisory firms for specialized biopharmaceutical
issues, finds the following key results, according to a recent BioTrends'
study, ChartTrends: Renal Anaemia in Chronic Kidney Disease - Non-Dialysis
(CKD-ND) and Dialysis, of 962 EU5 dialysis patient charts and 928 EU5 CKD-ND
patient charts:

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO)

  oErythropoiesis-stimulating agents (ESAs) treatment prevalence in both
    haemodialysis (HD) and peritoneal dialysis (PD) patient populations has
    declined from two years ago and the decline of 9 percent in HD reached
    statistical significance

  oSurveyed nephrologists significantly over-estimate the haemoglobin level
    at which they initiate ESAs in dialysis; this finding is pronounced in
    every EU5 country with the exception of Italy

  oESA treatment prevalence in the Stage 4 CKD-ND patient population is up 12
    percent from two years ago, according to 382 Stage 4 CKD-ND patient charts

  oNephrologists significantly underestimate their use of ESAs in Stage 4
    (predominately in France and Italy) and directionally in Stage 5
    non-dialysis (significantly in Italy)

  oAranesp (Amgen), Eprex/Erypo (Janssen-Cilag), NeoRecormon (Roche) and
    Mircera (Roche) and collectively ESA biosimilars are leading the dialysis
    market. In particular, ESA biosimilars in the dialysis population have
    reached mid-teen double-digit patient share, but use is much less in the
    CKD-ND patient population

  oHD IV iron treatment prevalence has remained flat from two years ago, but
    nephrologists over-estimate the use of IV iron in PD and under-estimate
    the use of oral iron in PD

  oIn CKD-ND, Venofer (Vifor Pharmaceuticals), Ferinject (Vifor
    Pharmaceuticals) and Ferrlecit (Sanofi) lead this space. Rienso, which
    recently launched in EU5 from Takeda Pharmaceuticals (developed by AMAG
    Pharmaceuticals), has captured minimal share at this point

"ESA cardiovascular warnings and cost containment pressures may be the reason
for these declining ESA treatment prevalences found in the dialysis patient
charts," said Rob Dubman, BioTrends' Director of Nephrology.

ChartTrends: Renal Anaemia in Chronic Kidney Disease - Non-Dialysis (CKD-ND)
and Dialysis is a syndicated report series, in which 210 nephrologists
provided patient chart data on 962 dialysis patients in the EU5 and 191
nephrologists provided patient chart data on 928 CKD-ND patients in the EU5 in
the most recent wave of research to uncover the actual management related to
renal anaemia. Through an in-depth review of patient charts, details such as
product dosing and titration, switching, concomitant medications and a host of
laboratory and patient demographic variables help define patient types and
identify therapy triggers.

The study also evaluated referral patterns, co-morbidities, blood
transfusions, hospitalizations and a host of other patient demographics and
laboratory data. BioTrends is publishing ChartTrends: Renal Anemia in dialysis
and CKD-ND reports later this year in the US. Additional ChartTrends Dialysis
reports have been published in China and Latin America (Brazil, Argentina and
Mexico).

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market
research to pharmaceutical manufacturers competing in clinically evolving,
specialty pharmaceutical markets. For information on BioTrends publications
and research capabilities, please contact us at (610) 321-9400 or
www.bio-trends.com.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers
best-in-class, high-value information and insights on important sectors of the
healthcare industry. Clients rely on this analysis and data to make informed
decisions. Please visit Decision Resources Group
atwww.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be
trademarks of their respective holders.



For more information, contact:


BioTrends Research Group, LLC Decision Resources Group
Rob Dubman                    Christopher Comfort
781-993-2592                  781-993-2597
rdubman@bio-trends.com        ccomfort@dresources.com

SOURCE BioTrends Research Group

Website: http://www.bio-trends.com
 
Press spacebar to pause and continue. Press esc to stop.